This finding has important implications for current therapeutic protocols that involve the clinical use of this JAK3 inhibitor for the therapy of rheumatoid arthritis, a variety of gut associated diseases including Crohn's, ulcerative colitis and IBD [51], [86]–[89]. This evidence concerns the gene JAK3 and inflammatory bowel disease.